L. Gu

发表

Comparison of Characteristics Between Chinese Patients Taking Glucagon-like Peptide 1 Receptor Agonists and Insulin: A Cross-sectional Database Analysis.

K. Boye, Ke Wang, S. Qu, 2019, Clinical therapeutics.

Lixisenatide Improves Glycemic Control in Asian Type 2 Diabetic Patients Inadequately Controlled With Oral Antidiabetic Drugs: An Individual Patient Data Meta-Analysis

Ju-ming Lu, L. Gu, L. Men, 2016, Diabetes Therapy.

Effect of pioglitazone on type 2 diabetes

L. Gu, 2014 .

Treatment of patients with diabetic peripheral neuropathic pain in China: a double-blind randomised trial of duloxetine vs. placebo

Y. Gao, Q. Li, G. Yang, 2015, International journal of clinical practice.

Achieving the composite end‐point of glycated hemoglobin <7.0% without weight gain or hypoglycemia with once‐weekly dulaglutide in Chinese patients with type 2 diabetes: A post‐hoc analysis

Xinhua Xiao, Zhiguang Zhou, L. Gu, 2019, Journal of diabetes investigation.

Efficacy and safety of once‐weekly dulaglutide versus insulin glargine in mainly Asian patients with type 2 diabetes mellitus on metformin and/or a sulphonylurea: A 52‐week open‐label, randomized phase III trial

Weiqing Wang, B. Tao, E. Filippova, 2018, Diabetes, obesity & metabolism.

Efficacy and safety of dulaglutide monotherapy compared with glimepiride in East‐Asian patients with type 2 diabetes in a multicentre, double‐blind, randomized, parallel‐arm, active comparator, phase III trial

Y. Cho, Chien-Ning Huang, L. Gu, 2018, Diabetes, obesity & metabolism.

Glycemic Control in Chinese Patients with Type 2 Diabetes Mellitus Receiving Oral Antihyperglycemic Medication-Only or Insulin-Only Treatment: A Cross-Sectional Survey

B. Curtis, Yun Chen, L. Gu, 2015, Diabetes Therapy.